Survival Benefit From Corticosteroids in Severe Alcohol-associated Hepatitis Attributed to Clinical and Treatment Differences in a Large Multicenter Cohort.

Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101532142 Publication Model: Electronic Cited Medium: Internet ISSN: 2155-384X (Electronic) Linking ISSN: 2155384X NLM ISO Abbreviation: Clin Transl Gastroenterol Subsets: MEDLINE

Publication: <2019-> : [Philadelphia, PA] : Wolters Kluwer Health
Original Publication: New York, NY : Nature Pub. Group

Hepatitis, Alcoholic*/drug therapy ; Hepatitis, Alcoholic*/mortality ; Hepatitis, Alcoholic*/complications ; Hepatitis, Alcoholic*/diagnosis ; Adrenal Cortex Hormones*/therapeutic use ; Adrenal Cortex Hormones*/adverse effects; Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; United States/epidemiology ; Severity of Illness Index ; Aged ; Hospitalization/statistics & numerical data ; Treatment Outcome

Introduction: Corticosteroids are recommended by multiple society guidelines for the treatment of severe alcohol-associated hepatitis (AH). However, their use remains controversial due to inconsistent studies regarding their survival benefit.
Methods: This was a retrospective cohort study of first-time hospitalizations for severe AH (Maddrey discriminant function ≥ 32) admitted to the Veterans Health Administration between January 3, 2005, and December 5, 2020, (i) evaluating the effect of corticosteroid therapy on all-cause survival, (ii) characterizing the clinical and psychosocial factors associated with corticosteroid use, and (iii) determining the effect of duration of corticosteroid therapy on all-cause survival among treatment-responsive patients (Lille score < 0.45).
Results: During the study period, 2,618 patients were admitted with severe AH, of whom 1,083 (41.37%) received corticosteroids. Although corticosteroids were significantly associated with improved all-cause survival in the unadjusted model ( P = 0.022), no survival benefit was observed in the adjusted model after accounting for baseline and admission characteristics (adjusted hazard ratio [aHR] = 1.01, P = 0.818). Psychiatry consultation was the only factor evaluated that was protective against mortality (aHR = 0.67, P < 0.001). Among the 428 patients (49.7%) responsive to corticosteroids, duration of therapy was not associated with overall survival on unadjusted ( P = 0.696) or adjusted models (aHR = 1.12, P = 0.710 for a ≥28-day course compared with a ≤7-day reference).
Discussion: Despite being recommended by clinical guidelines for severe AH, corticosteroids have low utilization with no survival benefit after accounting for differences in patient characteristics and practice patterns. Among patients with treatment response per the Lille score, no difference was observed in overall survival between shorter and longer durations of corticosteroid therapy.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)

Cochrane Database Syst Rev. 2019 Apr 09;4:CD001511. (PMID: 30964545)
J Hepatol. 2021 Nov;75(5):1026-1033. (PMID: 34166722)
Hepatol Commun. 2023 Mar 24;7(4):. (PMID: 36972386)
Am J Gastroenterol. 2022 Jul 1;117(7):1097-1105. (PMID: 35347088)
PLoS One. 2014 Jul 11;9(7):e100870. (PMID: 25013906)
Healthcare (Basel). 2021 May 18;9(5):. (PMID: 34070037)
Hepatology. 2020 Jan;71(1):306-333. (PMID: 31314133)
Am J Gastroenterol. 2018 Feb;113(2):175-194. (PMID: 29336434)
Clin Transplant. 2020 Sep;34(9):e14003. (PMID: 32506677)
Gastroenterology. 2018 Mar;154(4):965-975. (PMID: 29158192)
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e289-e297. (PMID: 33516950)
Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):689-99. (PMID: 21626605)
Aliment Pharmacol Ther. 2014 Apr;39(7):721-32. (PMID: 24612165)
Gastroenterology. 2015 Oct;149(4):958-70.e12. (PMID: 26091937)
Gastroenterology. 2018 Aug;155(2):458-468.e8. (PMID: 29738698)
J Gastroenterol. 2017 Nov;52(11):1192-1200. (PMID: 28389732)
Gut. 1995 Jul;37(1):113-8. (PMID: 7672658)
Hepatology. 2007 Mar;45(3):797-805. (PMID: 17326206)
Aliment Pharmacol Ther. 2008 Jun;27(12):1167-78. (PMID: 18363896)
Arch Intern Med. 1998 Sep 14;158(16):1789-95. (PMID: 9738608)
Subst Abus. 2022;43(1):1197-1206. (PMID: 35657656)
J Clin Gastroenterol. 2017 Apr;51(4):364-377. (PMID: 27636406)
Gastroenterology. 2015 Nov;149(6):1471-1482.e5; quiz e17-8. (PMID: 26255044)
Gut. 2011 Feb;60(2):255-60. (PMID: 20940288)
J Hepatol. 2018 Jul;69(1):154-181. (PMID: 29628280)
Hepatology. 2020 Jun;71(6):2080-2092. (PMID: 31758811)
Dig Dis Sci. 2022 Sep;67(9):4395-4402. (PMID: 35022905)
Hepatology. 2019 Apr;69(4):1477-1487. (PMID: 30561766)
Am J Gastroenterol. 2017 Feb;112(2):306-315. (PMID: 27922027)
Hepatology. 2021 Jan;73(1):204-218. (PMID: 32939786)
Gastroenterol Hepatol (N Y). 2016 Aug;12(8):478-489. (PMID: 27917083)
Gastroenterology. 2015 Aug;149(2):398-406.e8; quiz e16-7. (PMID: 25935634)
Gastroenterology. 2009 Aug;137(2):541-8. (PMID: 19445945)
Alcohol Clin Exp Res. 2016 Jun;40(6):1295-303. (PMID: 27147285)
Drug Alcohol Depend. 2014 Feb 1;135:95-103. (PMID: 24360928)
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2333-41.e1-6. (PMID: 26188137)
Hepatology. 2007 Jun;45(6):1348-54. (PMID: 17518367)
Am J Public Health. 2015 Dec;105(12):2564-9. (PMID: 26474009)
Hepatol Commun. 2023 Mar 30;7(4):. (PMID: 36996031)
Ann Hepatol. 2023 May-Jun;28(3):101088. (PMID: 36933885)
J Gen Intern Med. 2011 Mar;26(3):299-306. (PMID: 20859699)
Gastroenterology. 1978 Aug;75(2):193-9. (PMID: 352788)
J Hepatol. 2002 Apr;36(4):480-7. (PMID: 11943418)
Liver Transpl. 2019 Aug;25(8):1142-1154. (PMID: 30920118)
Hepatol Commun. 2021 Dec;5(12):2096-2103. (PMID: 34558860)

R01-DKDK070869 United States DK NIDDK NIH HHS; R01-AA030963 United States AA NIAAA NIH HHS; T32 DK007740 United States DK NIDDK NIH HHS; T32-DK007740 United States DK NIDDK NIH HHS; R01 AA030963 United States AA NIAAA NIH HHS

0 (Adrenal Cortex Hormones)

Date Created: 20241202 Date Completed: 20250124 Latest Revision: 20250129

20250129

PMC11756888

10.14309/ctg.0000000000000791

39620604